This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Zyga Technology Completes Enrollment In GLISSADE Study To Demonstrate Performance Of Facet Resurfacing

MINNEAPOLIS, Jan. 31, 2013 /PRNewswire/ -- Zyga Technology, Inc., a medical device company, today announced that it has completed enrollment in the GLISSADE Trial, a prospective, 40-patient trial that studied the GLYDER® Facet Resurfacing System in the treatment of chronic facetogenic pain. Preliminary data analyses from this five-site trial indicate a significant reduction in pain and improvement in function as measured by Visual Analogue Pain Scale (VAS) and Oswestry Disability Index (ODI). The results of this trial will serve as the foundation for future investigation including the DUET Clinical Trial in Europe and the U.K., and mid-2013 submission for an Investigational Device Exemption (IDE) Study to the U.S. Food and Drug Administration (FDA). The company anticipates CE Marking approval in late 2013.


The Centers for Disease Control and Prevention lists low back pain (LBP) as the second most common cause of disability in US adults[i]. Ten percent of the U.S. population, over 31 million people, suffer from chronic low back pain[ii]. Approximately 31% of chronic low back pain is attributed to the facet joints[iii], small stabilizing joints located between and behind adjacent vertebrae.

 "For patients suffering from chronic facet pain, there has never been a viable procedure providing long term relief," said Prof. Dr. Hans Jorg Meisel, Director of the Center of Neurosciences of the BG-Clinic Bergmannstrost Halle, Germany. "Their options were to receive injections several times each year or to undergo a more aggressive, permanent spine fusion procedure. The GLYDER System offers simple, minimally invasive implantation of a device designed to preserve the patient's anatomy and to provide long-term pain relief. Our initial patients are now reaching two years post-surgery, and we are very encouraged to see that they are experiencing sustainable pain relief."

"We are very encouraged by the preliminary results in the GLISSADE Trial, and the available data suggest the GLYDER System's clinical and economic value," said Jim Bullock, president and chief executive officer of Zyga Technology. "Facet joint injections have risen steadily over the past decade. This study has indicated how GLYDER Facet Resurfacing provides a safe, appropriate, clinically effective treatment for facetogenic pain and will pave the way for a successful IDE submission later in the second quarter of this year."

About Zyga Technology

Zyga Technology is dedicated to the research, development and commercialization of solutions that provide empirical clinical and economic value in the treatment of under-served conditions of the spine. The company is currently marketing the SImmetry® Sacroiliac Joint Fusion System, a minimally invasive procedure intended for conditions including sacroiliac joint disruptions and degenerative sacroiliitis. Zyga Technology is headquartered in Minneapolis, Minn. For more information, please visit

[i] Centers for Disease Control and Prevention. Prevalence of disabilities and associated health conditions among adults—United States, 1999. JAMA. 2001; 285(12):1571-1572.

[ii] Freuberger, JK et al. The Rising Prevalence of Low Back Pain. Arch Intern Med 2009; 169(3): 251 - 258.

[iii] DePalma M et al. What is the source of chronic low back pain and does age play a role? Pain Med 2011; 12:224 – 233.

CONTACT: Paul HessTel 612 455 1061 Ext. 112

SOURCE Zyga Technology, Inc.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.03 -2.90%
FB $116.73 7.20%
GOOG $691.02 -2.10%
TSLA $247.54 -1.60%
YHOO $36.59 -0.97%


Chart of I:DJI
DOW 17,830.76 -210.79 -1.17%
S&P 500 2,075.81 -19.34 -0.92%
NASDAQ 4,805.2910 -57.85 -1.19%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs